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Abstract 
Background and aims: TRIM5 and TRIM22 are restriction factors involved in innate immune response and exhibit 
anti‑viral activity. Single nucleotide polymorphisms (SNPs) at TRIM5 and TRIM22 genes have shown to influence sev‑
eral viral infections such as human immunodeficiency virus (HIV), hepatitis B, as well as measles and rubella vaccina‑
tion. The aim of this study is to analyze whether TRIM5 and TRIM22 polymorphisms are associated with liver fibrosis 
inflammation‑related biomarkers and response to pegylated‑interferon‑alpha plus ribavirin (pegIFNα/RBV) therapy in 
HIV/hepatitis C virus (HCV) coinfected patients.
Methods: A retrospective study was performed in 319 patients who started pegIFNα/RBV therapy. Liver fibrosis 
stage was characterized in 288 patients. TRIM5 rs3824949 and TRIM22 polymorphisms (rs1063303, rs7935564, and 
rs7113258) were genotyped using the GoldenGate assay. The primary outcomes were: a) significant liver fibrosis (≥F2) 
evaluated by liver biopsy or transient elastography (liver stiffness values ≥7.1 Kpa); b) sustained virological response 
(SVR) defined as no detectable HCV viral load (<10 IU/mL) at week 24 after the end of the treatment. The secondary 
outcome variable was plasma chemokine levels.
Results: Patients with TRIM5 rs3824949 GG genotype had higher SVR rate than patients with TRIM5 rs3824949 
CC/CG genotypes (p = 0.013), and they had increased odds of achieving SVR (adjusted odds ratio (aOR = 2.58; 
p = 0.012). Patients with TRIM22 rs1063303 GG genotype had higher proportion of significant liver fibrosis than 
patients with rs1063303 CC/CG genotypes (p = 0.021), and they had increased odds of having significant hepatic 
fibrosis (aOR = 2.19; p = 0.034). Patients with TRIM22 rs7113258 AT/AA genotype had higher SVR rate than patients 
with rs7113258 TT genotypes (p = 0.013), and they had increased odds of achieving SVR (aOR = 1.88; p = 0.041). The 
TRIM22 haplotype conformed by rs1063303_C and rs7113258_A was more frequent in patients with SVR (p = 0.018) 
and was significantly associated with achieving SVR (aOR = 2.80; p = 0.013). The TRIM5 rs3824949 GG genotype was 
significantly associated with higher levels of GRO‑α (adjusted arithmetic mean ratio ((aAMR) = 1.40; p = 0.011) and 
MCP‑1 (aAMR = 1.61; p = 0.003).
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/




*Correspondence:  sresino@isciii.es 
1 Unidad de Infección Viral e Inmunidad, Centro Nacional de 
Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), 
Carretera Majadahonda‑ Pozuelo, Km 2.2, 28220, Majadahonda, Madrid, 
Spain
Full list of author information is available at the end of the article
Page 2 of 10Medrano et al. J Transl Med  (2016) 14:257 
Background
The natural history of chronic hepatitis C (CHC) is 
highly variable in progression rates after decades with 
hepatitis C virus (HCV) infection. Disease progression 
may vary from minimal changes to advanced fibrosis, 
cirrhosis, end-stage liver disease, hepatocellular carci-
noma, and liver related death [1]. The development of 
hepatic fibrosis in CHC is multi-factorial and many co-
factors, which increase the individual risk of progres-
sion, have been identified [2]. In this regard, human 
immunodeficiency virus (HIV) is the most important 
co-infection factor identified [2]. Hepatitis C and HIV 
share routes of transmission, and HIV/HCV co-infec-
tion is quite common [1]. Co-infection with HIV and 
HCV has a negative impact on the natural history of 
HCV because HIV accelerates the risk of liver disease 
progression [3, 4], roughly 34 % of co-infected patients 
increase at least one METAVIR fibrosis stage over 
2.5 years [5].
Staging of liver fibrosis is essential for adequate man-
agement of patients with CHC, because it provides prog-
nostic information and facilitates decisions on therapy [6, 
7]. To date, hepatic biopsy is the gold standard to diag-
nosis and quantification of liver fibrosis [8]. In order to 
assess liver biopsy specimens, several systems have been 
developed, being METAVIR scoring system one of the 
most widely used [9], which ranks fibrosis on a 5-point 
scale from F0 (no fibrosis) to F4 (cirrhosis).
The standard of care for CHC was pegylated-inter-
feron-alpha plus ribavirin (pegIFNα/RBV) during many 
years [10], but this treatment limited the rate of sustained 
virological response (SVR) and severe associated adverse 
events, particularly in HIV/HCV coinfected patients [11]. 
Today, the new IFN-free therapies with direct-acting 
antivirals (DAAs) display SVR rates above 95 %, includ-
ing HIV/HCV co-infected patients [12]. Exceptionally, 
pegIFNα/RBV or pegIFNα/RBV plus DAAs may be used 
in groups of patients [13]. Therefore, the use of pegIFNα/
RBV has dropped drastically and it is no longer recom-
mended therapy for HIV/HCV coinfected patients. How-
ever, the access to the newer HCV drugs may be limited 
in certain countries or regions due to its high cost.
The tripartite motif (TRIM) family, RING finger E3 
ubiquitin ligases, comprise around 100 host restriction 
factors with a potent antiviral activity against HIV [14] and 
other viruses such as HCV [15]. The restriction factors are 
part of the innate immune response and normally respond 
to IFN stimulation [IFN-stimulated genes (ISGs)] [16, 17]. 
TRIM proteins are also involved in apoptosis, transcrip-
tion, differentiation and regulation of cell cycle progres-
sion, and some TRIM proteins exhibit anti-viral activity 
[18, 19]. TRIM5 is well known to restrict the HIV-1 infec-
tion at an early-stage of reverse transcription [14]. Fur-
thermore, TRIM5 is an E3 ubiquitin ligase that promotes 
activation of nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) and activator protein 1 (AP-1), 
which play an important role in innate immune response 
[20, 21]. TRIM22 protein, as well as TRIM5, is an ISG 
upregulated upon IFN administration to HCV-infected 
patients and it is also able to induce innate signaling path-
ways [15, 22]. TRIM22 is a natural antiviral effector of 
HIV-1 [23]. The TRIM22 expression has been negatively 
correlated with low HIV-1 plasma viral load and high lev-
els of CD4+ T cell count [24]. Moreover, there is also evi-
dence that TRIM22 is involved in blocking replication of 
HCV [15, 25] and hepatitis B virus (HBV) [26].
Genetic factors may play an important role for HCV 
treatment response and disease progression in CHC [27], 
such as polymorphisms located around IL28B region that 
have been described as predictors of spontaneous HCV 
clearance and CHC treatment [28]. TRIM5 and TRIM22 
genes are adjacent and located on chromosome 11 [29]. 
Single nucleotide polymorphisms (SNPs) at TRIM5 and 
TRIM22 genes have been implicated in several infec-
tions such as HIV [14, 30], HBV [31], and measles and 
rubella vaccination [32, 33]. However, there are not any 
data about the influence of TRIM5 and TRIM22 SNPs on 
CHC.
The aim of this study was to analyze whether TRIM5 
and TRIM22 polymorphisms are associated with liver 
fibrosis inflammation-related biomarkers and response to 
pegIFNα/RBV therapy in HIV/HCV coinfected patients.
Methods
Patients and study design
We carried out a retrospective study in HIV/HCV 
coinfected patients who started HCV treatment with 
pegIFNα/RBV on a regular follow-up at two reference 
HIV hospitals located in Madrid, Spain: Hospital Gen-
eral Universitario “Gregorio Marañón” and Hospital 
Carlos III. The study was approved by the Research Ethic 
Committee of the Instituto de Salud Carlos III and was 
Conclusions: TRIM5 and TRIM22 SNPs are associated to increased odds of significant liver fibrosis and SVR after 
pegIFNα/RBV therapy in HIV/HCV coinfected patients. Besides, TRIM5 SNP was associated to higher baseline levels of 
circulating biomarkers GRO and MCP‑1.
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conducted in accordance with the Declaration of Hel-
sinki. All patients gave their written informed consent.
The inclusion criteria for starting HCV antiviral treat-
ment were: HIV infection, chronic hepatitis C (presence 
of detectable HCV replication for at least 6 months after 
HCV infection), negative hepatitis B surface antigen, no 
clinical evidence of hepatic decompensation, detect-
able HCV RNA by polymerase chain reaction at base-
line, CD4+  count higher than 200 cells/mm3, and stable 
combination antiretroviral therapy (cART) for at least 
6  months before study entry or no need according to 
treatment guidelines used in the study period [10, 34]. The 
exclusion criteria were: active opportunistic infections, 
active drug or alcohol addiction, and other concomitant 
diseases or conditions. A total of 331 patients had avail-
able DNA samples, but 12 patients were excluded due to 
genotyping problems. Finally, 319 patients were available 
for genetic association analysis (Fig. 1).
Epidemiological and clinical data
Clinical and epidemiological data were obtained from 
medical records. Body mass index (BMI) was calculated 
as the weight in kilograms divided by the square of the 
height in meters. The duration of HCV infection for 
patients with a history of intravenous drug use (IDU) was 
estimated starting from the first year they shared needles 
and other injection paraphernalia, which are the most 
relevant risk practices for HCV transmission. For non-
IDU patients, we only included those patients for whom 
the initiation of their HCV infection could be deter-
mined with certainty. In this case, the initiation of HCV 
infection was determined only when patients reported 
an approximate date of transfusion prior to the intro-
duction of HCV screening on blood donations, surgical 
intervention, or other HCV risk practices (sexual contact, 
needle piercing, etc.).
CD4+  cell counts is used to assess the HIV disease 
stage [35]. HIV-infected patients with a good immune 
system have a CD4+ count ranges from 500 to 1200 cells/
mm3. A CD4+  cell counts between 200 and 500  cells/
mm3 increases the risk for certain infections, such as 
shingles, thrush, skin infections, bacterial sinus and lung 
infections, and tuberculosis. A CD4+  count of fewer 
than 200 cells/mm3 is a clinical criterion for diagnosis of 
stage 3 infection (AIDS).
Liver biopsy
Liver fibrosis was assessed by different methods, depend-
ing on the Hospital: (a) At Hospital General Universitario 
“Gregorio Marañón” liver biopsy was used and fibrosis 
was estimated according to Metavir score as follows: F0, 
non-fibrosis; F1, mild fibrosis; F2, significant fibrosis; 
F3, advanced fibrosis; and F4, definite cirrhosis. (b) At 
Hospital Carlos III transient elastography (FibroScan®, 
Echosens, Paris, France) was used, and liver stiffness 
values ≤7.0, between 7.1 and 9.4, between 9.5 and 12.4, 
and ≥12.5 were considered to correspond with Metavir 
scores F0-F1, F2, F3, and F4, respectively [36].
Hepatitis C therapy
Following both international and national guidelines 
[10, 34], HCV treatment regimens included pegIFNα 
2a or 2b at standard doses (180  µg/week or 1.5  µg/kg/
week, respectively) plus weight-adjusted ribavirin dos-
ing (1000  mg/day for patients weighing  <75  kg and 
1200 mg/day for patients weighing ≥75 kg). The virologic 
response to HCV treatment was measured by assessing 
plasma HCV-RNA at 4, 12 weeks, end-of-treatment, and 
Fig. 1 Flow diagram of selection of patients and study design
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24  weeks after HCV treatment cessation. Patients with 
HCV genotypes 1 or 4 received either 48 or 72 weeks of 
treatment, and patients with HCV genotype 2 or 3 were 
treated for 24 or 48  weeks, depending on the virologic 
response at week 4.
Multiplex ELISA
A multiplex kit (Panomics Afymetrix, Inc.; Procarta® 
Protein Profiling Assays, Fremont, California, United 
States) was used to specifically evaluate six plasma bio-
markers according to the manufacturer’s specifications 
using the Luminex 100™ analyser (Luminex Corpora-
tion, Austin, TX, United States): IFN-γ-inducible protein 
10 (IP-10 or CXCL10), growth-regulated alpha protein 
(GRO-α or CXCL1), epithelial-derived neutrophil-acti-
vating peptide 78 (ENA-78 or CXCL5), eotaxin (CCL11), 
monocyte chemoattractant protein-1 (MCP-1 or CCL2), 
and monocyte chemoattractant protein-3 (MCP-3 or 
CCL7).
DNA genotyping
Genomic DNA was extracted from peripheral blood 
with Qiagen kit (QIAamp DNA Blood Midi/Maxi; 
Qiagen, Hilden, Germany). DNA samples were quan-
tified and sent to the Spanish National Genotyping 
Center (http://www.cegen.org/) for DNA genotyping 
by using GoldenGate® assay with VeraCode® Technol-
ogy (Illumina Inc. San Diego, CA, USA) according to 
the published Illumina protocol (http://support.illu-
mina.com/content/dam/illumina-support/documents/
myillumina/0569bf7e-c9ec-4961-8478-0b103e71eb04/
veracode_assay_guide_11312819_revb.pdf). The quality 
control was performed according to the CeGen criteria, 
which includes duplicated samples on each plate to check 
for technical replicates; negative and positive controls in 
each batch to exclude DNA contamination and ensure a 
technically correct laboratory process, respectively; gen-
otyping call-rate success over 95 % for all the SNPs and 
family-based studies to measure the genotyping error 
rate.
The criteria for selecting TRIM5 and TRIM22 poly-
morphisms were: (i) SNPs located in putative regulatory 
region; (ii) minor allelic frequency (MAF) greater than 
20 % for CEU (Utah residents with ancestry from North-
ern and Western Europe) and TSI (Toscan in Italy) Hap-
map population; (iii) selection of tagSNPs according to 
linkage disequilibrium (LD) >0.8. Finally, four SNPs were 
selected: rs3824949 in TRIM5 and rs7935564, rs1063303 
and rs7113258 in TRIM22.
Outcome variables
The outcome variables were: (a) significant liver fibrosis 
evaluated by liver biopsy (F ≥ 2) or transient elastography 
(liver stiffness values ≥7.1 Kpa); (b) levels of plasma bio-
markers of inflammation; (c) SVR defined as no detect-
able HCV viral load (<10 IU/mL) at week 24 after the end 
of the treatment.
Statistical analysis
For the description of the study population, p values were 
estimated with nonparametric tests: Mann–Whitney U 
test was used for continuous variables and Chi squared 
or Fisher’s exact test (when expected values were below 
5) for categorical variables.
The genetic association study was carried out accord-
ing to the genetic model that best fit our data (addi-
tive, recessive or dominant). Logistic regression analysis 
was used to investigate the relationship of TRIM5 and 
TRIM22 polymorphisms with outcome variables. Each 
logistic regression test was adjusted by the most sig-
nificant co-variables associated with each one of the 
outcome variables, avoiding the over-fitting of the regres-
sion. We included the SNP [Enter algorithm (forced entry 
for the SNP)] and the most relevant characteristics by 
stepwise algorithm (at each step, factors are considered 
for removal or entry: a p value for entry and exit of 0.15 
and 0.20, respectively). The covariables used were age, 
gender, BMI, baseline HCV-RNA viral load (<500,000 
vs. ≥500,000 IU/mL), significant fibrosis (F < 2 vs. F ≥ 2), 
Interleukin-28B (IL28B) rs12980275 polymorphism (AA 
vs. AG/GG), and HCV genotype [GT1/4 vs. GT2/3)]. 
Moreover, the association between TRIM5 and TRIM22 
polymorphisms and plasma biomarkers was investigated 
by using General Lineal Model (log-link) adjusted for 
the same variables described above. All statistical analy-
ses were performed by using the IBM SPSS Statistics for 
Windows, Version 22.0 (IBM Corp, Chicago, Armonk, 
NY, USA).
In addition, pair-wise linkage disequilibrium (LD) anal-
ysis was computed by Haploview 4.2 software. Haplotype 
frequencies were inferred with the Expectation–Maximi-
zation algorithm and haplotype-based association test-
ing was performed using PLINK software. All p values 
were two-tailed and statistical significance was defined as 
p < 0.05.
In silico analysis
The in silico analysis for possible functional implica-
tions of each polymorphism was evaluated by using four 
web-tools: (a) VarioWatch (http://genepipe.ncgm.sinica.
edu.tw/variowatch/); (b) rSNABase (http://rsnp.psych.
ac.cn/); (c) SIFT (http://sift.bii.a-star.edu.sg/index.html); 
(d) analysis for possible miRNA binding site according to 
each polymorphism was explored by using MicroSNiPer 
web tool (http://epicenter.ie-freiburg.mpg.de/services/
microsniper/).
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Results
Characteristics of patients and TRIM5 and TRIM22 
polymorphisms
The baseline characteristics of 319 HIV/HCV coin-
fected patients used in the current study are presented 
in Table  1. The median age was 42  years, 77.1  % were 
males and 84.0  % were on cART. The median baseline 
CD4+ count was 461 cells/mm3, 76.1 % had plasma HIV-
RNA <50 copies/mL, 63.3 % had significant liver fibrosis 
(≥F2), 26.2  % had plasma HCV-RNA  <500,000  UI/mL, 
and 45.8 % had the favorable genotype of IL28B polymor-
phism (AA rs12980275).
The allelic and genotypic frequencies for TRIM5 
and TRIM22 polymorphisms in HIV/HCV coinfected 
patients are shown in Additional file  1: Table  S1. The 
MAF was  >5  % and genotyping call-rate success was 
over 95 % for all the SNPs. The frequencies in our dataset 
were in accordance with the data listed on the NCBI SNP 
database (http://www.ncbi.nlm.nih.gov/projects/SNP/). 
Furthermore, TRIM5 and TRIM22 polymorphisms were 
in Hardy–Weinberg equilibrium (p  >  0.05), except for 
TRIM22 rs7935564 (p = 0.0035) which was discarded for 
the analysis of genetic association.
Genetic association of TRIM5 and TRIM22 polymorphisms
The association of TRIM5 and TRIM22 polymorphisms 
with outcome variables [significant fibrosis and SVR] 
in HIV/HCV coinfected patients are shown in Table  2. 
Patients with TRIM5 rs3824949 GG genotype had 
higher SVR rate than patients with TRIM5 rs3824949 
CC/CG genotypes (p  =  0.013), and they had increased 
odds of achieving SVR (adjusted odds ratio (aOR = 2.58; 
p =  0.012). Patients with TRIM22 rs1063303 GG geno-
type had higher proportion of significant fibrosis than 
patients with rs1063303 CC/CG genotypes (p  =  0.021), 
and they had increased odds of having significant fibro-
sis (aOR = 2.19; p = 0.034). Additionally, when we strati-
fied our data by baseline HCV-RNA viral load (<500,000 
vs. ≥500,000  IU/mL), we observed an almost significant 
association between rs1063303 GG genotype and sig-
nificant fibrosis in patients with high HCV viral load 
(aOR = 2.18; p = 0.070). Moreover, patients with TRIM22 
rs7113258 AT/AA genotype had higher SVR rate than 
patients with rs7113258 TT genotypes (p =  0.013), and 
they had increased odds of achieving SVR (aOR =  1.88; 
p = 0.041).
Haplotype frequencies of TRIM22 polymorphism 
(rs1063303 and rs7116258) stratified by outcome vari-
ables are presented in Table  3. The allelic combination 
conformed by rs1063303_C and rs7113258_A was more 
frequent in patients with SVR (p =  0.018) and was sig-
nificantly associated with the achievement of SVR 
(aOR = 2.80; p = 0.013).
Plasma chemokines
The association of TRIM5 rs3824949 polymorphism with 
levels of plasma biomarkers in HIV/HCV coinfected 
patients are shown in Table  4. Patients with rs3824949 
GG genotype had higher plasma levels of eotaxin 
(p =  0.038) and MCP-1 (p =  0.034) than patients car-
rying rs3824949 CC/CG genotypes. Besides, patients 
with rs3824949 GG genotype tended to have higher 
levels of GRO-α (p =  0.064). When multivariate analy-
sis was performed, rs3824949 GG genotype was signifi-
cantly associated with higher levels of GRO-α [adjusted 
Table 1 Main epidemiological and  clinical characteristics 
of HIV/HCV coinfected patients on HCV antiviral therapy
Values expressed as absolute number (percentage) and median (interquartile 
range)
BMI body mass index; IVDU intravenous drug users; HCV hepatitis C virus; HCV-
RNA HCV serum viral load; GT HCV genotype; HIV-1 human immunodeficiency 




Male 246 (77.1 %)
Age (years) 42 (38.7–45.9)
Anthropometric values
 Height (m) 1.7 (1.6–1.7)
 Weight (kg) 67 (60–75)
 BMI (kg/m2) 23.1 (21.2–25.4)
IVDU 281 (89.8 %)
 Time of HCV infection (months) 19.6 (12.7–23.5)
cART 268 (84.0 %)
HIV markers
 Nadir CD4+ T‑cells/μL 226 (132–341)
 Nadir CD4+ <200 cells/μL 135 (42.3 %)
 Baseline CD4+ T‑cells/μL (n = 316) 461 (364–670)
 Baseline CD4+ <500 T‑cells/μL (n = 316) 175 (55.4 %)
 HIV‑RNA <50 copies/ml (n = 314) 239 (76.1 %)
HCV markers
 HCV genotypes (n = 317)
  GT 1 179 (56.5 %)
  GT 2 1 (0.3 %)
  GT 3 100 (31.5 %)
  GT 4 37 (11.7 %)
HCV‑RNA (n = 313)
 HCV‑RNA <500,000 IU/mL 82 (26.2 %)
 Log10 HCV‑RNA (IU/mL) 6.1 (5.6–6.8)
IL28B polymorphism (rs12980275)
 AA 146 (45.8 %)
 AG 146 (45.8 %)
 GG 27 (8.5 %)
Liver fibrosis (n = 288)
 Significant fibrosis (F ≥ 2) 182 (63.3 %)
 Advanced fibrosis (F ≥ 3) 98 (33.9 %)
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arithmetic mean ratio (aAMR) =  1.40; p =  0.011] and 
MCP-1 (aAMR = 1.61; p = 0.003).
We did not find any significant differences in plasma 
biomarker levels according to the genotypes of TRIM22 
rs1063303 and rs7113258 (data not shown).
Discussion
The genetic variation of genes involved in innate immune 
system may influence the odds of clinical outcomes in 
CHC and HIV infection [27, 37]. In our study, patients 
with TRIM22 rs1063303 polymorphism was related to 
Table 2 Association of  TRIM5 rs3824949 and  TRIM22 rs1063303, rs7113258 polymorphism with  significant fibrosis 
(F ≥ 2) at baseline and sustained virological response (SVR) in HIV/HCV coinfected patients on HCV therapy
Categorical variables are expressed in percentage (absolute count)
Statistically significant differences are shown in italics
aOR adjusted odds ratio; 95 %CI 95 % confidence interval; HCV hepatitis C virus; HIV human immunodeficiency virus. TRIM5 tripartite motif-containing 5; TRIM22 
tripartite motif-containing 22
a p values were calculated by Chi square tests or Fisher’s exact test when expected values are below five
b p cvalues were calculated by logistic regression adjusting for the most important clinical and epidemiological characteristics (see statistical analysis section)
Unadjusted Adjusted
CC/CG GG p valuea aOR (95 % CI) p valueb
TRIM5 rs3824949 (Recessive)
 F ≥ 2 (n = 287) 31.6 % (142/225) 48.7 % (39/62) 0.976 0.84 (0.46–1.55) 0.589
 SVR (n = 318) 50.8 % (127/250) 67.6 % (46/68) 0.013 2.58 (1.23–5.39) 0.012
TRIM22 rs1063303 (Recessive)
 F ≥ 2 (n = 286) 59.8 %(140/234) 76.9 % (40/52) 0.021 2.19 (1.06–4.53) 0.034
 SVR (n = 317) 55.6 % (145/261) 48.2 % (27/56) 0.317 0.89 (0.41–1.91) 0.760
TRIM22 rs7113258 (Dominant) TT AT/AA p valuea aOR (95 % CI) p valueb
F ≥ 2 (n = 287) 63.3 % (124/196) 63.7 % (58/91) 0.939 1.06 (0.62; 1.82) 0.829
SVR (n = 317) 49.8 % (107/215) 64.7 % (66/102) 0.013 1.88 (1.03–3.38) 0.041
Table 3 Haplotype frequencies of  TRIM22 rs1063303 and  rs7113258 polymorphisms and  their genetic association 
with  significant fibrosis (F  ≥  2) at  baseline and  sustained virological response (SVR) in  HIV/HCV coinfected patients 
on HCV therapy
Statistically significant differences are shown in italics
aOR adjusted odds ratio; 95 %CI 95 % confidence interval; SVR sustained virological response; HCV hepatitis C virus; HIV human immunodeficiency virus
a p values were calculated by Chi square tests
b p values were calculated by logistic regression adjusting for the most important clinical and epidemiological characteristics (see ‘‘statistical analysis’’ section)
Haplotypes by fibrosis Frequency OR (95 % CI) p valuea aOR (95 % CI) p valueb
F < 2 (%) F ≥ 2 (%)
CT 49.5 47.0 0.88 (0.61–1.28) 0.509 0.91 (0.62–1.34) 0.627
GT 34.8 35.7 1.05 (0.71–1.55) 0.818 1.03 (0.68–1.54) 0.902
GA 8.6 8.2 0.94 (0.46–1.95) 0.876 0.88 (0.41–1.89) 0.749
CA 7.1 9.1 1.43 (0.69–2.95) 0.321 1.52 (0.68–3.37) 0.294
Haplotypes by HCV
treatment response
Non-SVR (%) SVR (%) OR (95 % CI) p valuea aOR (95 % CI) p valueb
CT 50.7 46.5 0.82 (0.58–1.15) 0.244 0.78 (0.51–1.18) 0.236
GT 36.5 33.3 0.84 (0.58–1.21) 0.345 0.86 (0.55–1.34) 0.496
GA 7.0 10.0 1.81 (0.90–3.61) 0.090 1.61 (0.67–3.88) 0.286
CA 5.9 10.2 2.29 (1.12–4.70) 0.018 2.80 (1.19–6.57) 0.013
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higher odds of having significant fibrosis, whereas TRIM5 
rs3824949 and TRIM22 rs7113258 polymorphisms were 
associated with achieving SVR and higher plasma levels 
of inflammation biomarkers.
Immunological response has a crucial role in viral 
persistence and liver damage during CHC [38, 39]. 
The development of fibrosis and cirrhosis depends on 
the functional diversity of this response and the bal-
ance between pro-inflammatory and anti-inflammatory 
response [39]. TRIM proteins are encoded by ISGs that 
are involved in the regulation of anti-viral innate immune 
response [18, 19]. TRIM proteins have a key role in the 
regulation of pathways downstream of viral RNA and 
DNA sensors, and in the inflammasome; besides, TRIMs 
may contribute to the development and pathology of 
autoimmune and autoinflammatory conditions [40].
TRIM22 is an interferon-induced protein that potently 
inhibits the replication of diverse viruses such as HIV-1 
[23], HCV [15, 25] and HBV [26]; and the overexpression 
of TRIM22 activates NF-κB in a dose-dependent man-
ner [41], promoting autoimmune diseases [42]. TRIM22 
SNPs have been related to several aspects of viral infec-
tions such as HIV replication [30], chronic hepatitis 
B infection [31], and levels of specific antibodies and 
cytokines following measles and rubella vaccination [32, 
33]. The TRIM22 rs1063303 G  >  C causes an arginine 
(R) to threonine (T) amino acid change at position 242 
in the TRIM22 protein [43]. The TRIM22 rs1063303 GG 
variant correlated to an inverse functional impact where 
it increased TRIM22 expression and decreased the anti-
viral activity of TRIM22 [43]. In this regard, the overex-
pression of TRIM22 negatively correlated with HCV viral 
load [25] and HIV-1 viral load [44], while gene silencing 
of TRIM22 enhanced HIV-1 infection of target cells [44]. 
Besides, the rs1063303 GG genotype has also been asso-
ciated with a more efficient HIV-1 replication [30]. In our 
study, the rs1063303 GG genotype was associated with 
significant fibrosis. Furthermore, we found an almost sig-
nificant association between rs1063303 GG genotype and 
significant fibrosis only in patients with high HCV viral 
load. It is possible that rs1063303 GG genotype might 
impair the control of HCV replication and could favor a 
more powerful inflammatory response, which could pro-
mote more efficiently the development of liver fibrosis.
Moreover, patients with TRIM22 rs7113258 TA/AA 
genotype had increased odds of achieving SVR after 
pegIFNα/RBV therapy. The rs7113258 polymorphism 
is located at a regulatory region [3′ untranslated region 
(UTR)]. Therefore, it could have a regulatory effect on 
the TRIM22 gene expression. In this setting, we ana-
lyzed in silico whether this TRIM22 rs7113258 could be 
part of microRNAs (miRNAs) binding sites via Micro-
SNiPer [45]. The miRNAs are negative gene regulators 
influencing gene expression by binding at the 3′UTR 
level [46]. We found that rs7113258 A allele generates 
putative target sites for several miRNAs (hsa-miR-4495, 
hsa-miR-3668 and hsa-miR-3148), whereas the pres-
ence of rs7113258 T allele disrupts these target sites and 
generates others (hsa-miR-4678 and hsa-miR-3177-5p). 
Thus, we might hypothesize that these differences in the 
miRNAs binding between rs7113258 genotypes could 
be implicated in the observed association. However, fur-
ther studies investigating the functional role of this SNP 
would be interesting and it should not be excluded that 
rs7113258 could be just a tagSNP in LD with the causal 
variant.
The LD analysis showed that there was low LD (non-
random association of alleles at different loci) between 
Table 4 Association of TRIM5 rs3824949 polymorphism with levels of plasma biomarkers in HIV/HCV coinfected patients 
at baseline
Data are expressed in median (interquartile range)
Statistically significant differences are shown in italics
aAMR adjusted arithmetic mean ratio; 95 %CI 95 % confidence interval; IP-10 or CXCL10 IFN-γ-inducible protein 10; GRO-α or CXCL1 growth-regulated alpha protein; 
ENA-78 or CXCL5 epithelial-derived neutrophil-activating peptide 78; CCL11 eotaxin; MCP-1 CCL2 monocyte chemoattractant protein; CCL7 MCP-3; HCV hepatitis C 
virus; HIV human immunodeficiency virus
a p values were calculated by Mann–Whitney test
b p values were calculated by General Lineal Model (GLM) after adjusting by the most important clinical and epidemiological characteristics (see ‘‘statistical analysis’’ 
section)
CC/CG GG p valuea aAMR (95 % CI) p valueb
IP‑10 or CXCL10 (pg/ml) 517.7 (573.8) 696.5 (979.4) 0.510 1.56 (0.94; 2.59) 0.082
GRO‑α or CXCL1 (pg/ml) 62.6 (47.3) 80.4 (33.0) 0.064 1.40 (1.08; 1.83) 0.011
ENA‑78 o CXCL5 (pg/ml) 93.4 (103.9) 114.2 (140.4) 0.391 1.26 (0.90; 1.76) 0.165
Eotaxin or CCL11 (pg/ml) 43.8 (55.5) 78.3 (67.5) 0.038 1.19 (0.89; 1.61) 0.234
MCP‑1 or CCL2 (pg/ml) 28.5 (42.1) 64.3 (82.9) 0.034 1.61 (1.18; 2.19) 0.003
MCP‑3 or CCL7 (pg/ml) 16.2 (17.6) 18.6 (15.7) 0.973 0.91 (0.66; 1.24) 0.543
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TRIM22 SNPs (D’  =  0.14), meaning that there is evi-
dence of a possible recombination between these SNPs. 
Moreover, the R-squared among TRIM22 SNPs was low 
(R2  =  0.01), meaning that the TRIM22 SNPs did not 
provide exactly the same information and could not be 
substituted one for the other. Taking into account these 
results, it is very important to perform allelic combina-
tion analysis between these two variants in order to 
better explore the genetic variance in this region. We 
observed that the allelic combination conformed by 
rs1063303_C and rs7113258_A increased the likelihood 
of SVR after pegIFNα/RBV therapy, with a higher odd 
ratio (OR  =  2.80) than rs7113258 alone (OR  =  1.88). 
Though we did not observe any association between 
TRIM22 rs1063303 CC genotype and SVR, which may 
be due to the limited sample size. Thus, our study could 
have enough statistic power to detect differences in 
rs1063303 when combined with rs7113258 because more 
genetic variability is captured, but not when this SNP is 
analyzed alone. The allelic combinations in TRIM22 give 
us an increased knowledge about possible genetic effect 
in the loci. The causal variant in the region could be in 
LD with the combination of rs1063303_C-rs7113258_A.
On the other hand, TRIM5 protein restricts the HIV-1 
replication but their exact antiviral mechanism remains 
unclear [14]. Furthermore, TRIM5 could act as a pattern 
recognition receptor that triggers the E3-ubiquitin ligase 
activity, leading to the activation of the NF-κB and AP-1 
and promoting innate immune response [14]. Other 
TRIM5 polymorphisms (rs10838525 and rs3740996) 
have been related to higher resistance to HIV-1 infection 
[14] and TRIM5 rs3824949 GG is associated with higher 
levels of antibodies in response to measles and rubella 
vaccines [32, 33]. Our results show that patients with 
TRIM5 rs3824949 GG genotype had higher likelihood 
of achieving SVR. The TRIM5 rs3824949 polymorphism 
is located at 5′ UTR. 5′ UTR region is already known to 
play crucial roles in the post-transcriptional regulation 
of gene expression [47]. We analyzed in silico whether 
this TRIM5 rs3824949 could be a part of RNA binding 
protein site via rSNPBase [48]. We found that rs3824949 
is involved in RNA binding protein-mediated post-tran-
scriptional regulation. Additionally, rs3824949 shows an 
eQTL (expression quantitative trait loci) effect, meaning 
that there is evidence for a direct functional relationship 
between the rs3824949 polymorphism and the measured 
expression levels of different genes. It is possible that the 
rs3824949 polymorphism may influence the expression 
of TRIM5 gene at the level of translation, favoring HCV 
eradication after pegIFNα/RBV therapy.
In addition, patients with TRIM5 rs3824949 GG gen-
otype had higher levels of plasma chemokines. GRO-α 
(CXCL-1), MCP-1 (CCL-2), and eotaxin (CCL-11) are 
members of the chemokine family, which are secreted by 
the liver during chronic HCV infection, and their levels 
are strongly associated with lymphocyte recruitment, 
immune response, and fibrogenesis [49, 50]. CXCL-1 is 
a potent agonist for CXCR2 which recruits neutrophils 
to the site of inflammation or injury during liver disease 
[51], and plasma levels of CXCL1 are associated with 
liver fibrosis in HCV-infected patients [52]. MCP-1 is 
a potent agonist for CCR2, this chemokine participates 
in regulating Th2 lymphocyte subset infiltration in liver 
[49, 50]. CCL-11 is a chemokine that selectively recruits 
eosinophils, basophils and Th2 lymphocytes through 
CCR3 [53]. Then, patients with rs3824949 GG genotype 
seem to have a predominant Th2 immune profile. More-
over, it has been reported that non-responder patients 
to IFN-α therapy show preactivation of their IFN sys-
tem and have some defects at steps downstream of ISG 
expression, making them refractory to both endogenous 
IFN-α and IFN-α therapy [54]. Thus, these chemokines 
may reflect the degree of Th2 immune responses, and 
under this scenario, patients with an increased Th2 pro-
file may indicate a healthy Th1 immune response and 
low preactivation of their IFN pathway, making them 
more responsive to pegIFNα/RBV therapy.
Finally, several aspects have to be taken into account 
for the correct interpretation of the results. Firstly, this 
report has a retrospective design with a relatively small 
number of patients, which could limit the statistical 
power to detect differences between groups. Secondly, 
the patients selected for our study were patients who 
met a set of criteria for starting HCV treatment, and it 
is possible that this may have introduced a selection bias. 
Thirdly, we had no access to HCV-monoinfected patients 
in order to evaluate the influence of TRIM5 and TRIM22 
polymorphisms on these patients. Moreover, since the 
study was carried out entirely in European whites, and 
the frequency of these alleles differs among different eth-
nicities, it would be necessary to perform an independent 
replication of this study for different ethnic groups.
Conclusion
In summary, the major findings were: (1) The TRIM22 
rs1063303 GG genotype was associated with having sig-
nificant fibrosis; (2) The TRIM5 rs3824949 GG genotype 
and TRIM22 rs7113258 TA/AA genotypes were associ-
ated with achieving SVR; (3) The TRIM22 haplotype con-
formed by rs1063303_C and rs7113258_A was associated 
with achieving SVR; (4) The TRIM5 rs3824949 GG geno-
type was associated with having high plasma levels of 
GRO-α and MCP-1. These data suggest that TRIM2 and 
TRIM5 polymorphisms may play a major role in patho-
genesis of CHC in HIV/HCV coinfected patients. Further 
researches are necessary to corroborate these findings.
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